Document is current
Any future updates will be listed below
-
Authors
Shigematsu, Yasuyuki
Kanda, Hiroaki
Takahashi, Yu
Takeuchi, Kengo
Inamura, Kentaro https://orcid.org/0000-0001-6444-3861
-
Funding
Funding for this research was provided by:
JSPS KAKENHI (JP22H02930, JP23K18246, JP23K14491)
- License Information
-
More Information
Article History
Received: 5 July 2024
Revised: 2 September 2024
Accepted: 29 September 2024
First Online: 12 October 2024
Declarations
:
: All procedures followed were in accordance with the ethical standards of the responsible committee on human experimentation (institutional and national) and with the Helsinki Declaration of 1975, as revised in 2008. The study was approved by the Ethics Committee of the Japanese Foundation for Cancer Research (approval reference number: 2017-GA-1136). The requirement for informed consent was waived because of the retrospective study design.
: Yasuyuki Shigematsu, Kengo Takeuchi, and Kentaro Inamura received a research grant and materials including the anti-CD147 antibody (clone E1S1V) and cell array for positive and negative control of CD147 expression from Daiichi Sankyo Co., Ltd., which may represent a conflict of interest. Hiroaki Kanda and Yu Takahashi declare that they have no conflict of interest.
